Boehringer, ViraTherapeutics in oncolytic virus deal

Boehringer Ingelheim GmbH (Ingelheim, Germany) partnered with oncolytic virus play ViraTherapeutics GmbH (Innsbruck, Austria) to jointly develop ViraTherapeutics' oncolytic virus therapy platform and its lead candidate, VSV-GP.

Boehringer also gained an option to acquire ViraTherapeutics after Phase I testing of VSV-GP is complete. The companies said the deal has a potential value of EUR 210 million ($235.8 million), but did not provide details and did not respond to inquiries. ...